Methods and compositions for treating chronic lung diseases

JP2025114869A5Active Publication Date: 2025-10-20OAK HILL BIO LTD
0 Cites 0 Cited by

Patent Information

Application Number
JP2025086115
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2017-09-11
Filing Date
2025-05-23
Publication Date
2025-10-20
Estimated Expiration
2038-09-11

AI Technical Summary

Technical Problem

Premature infants are at high risk for developing chronic lung disease (CLD), particularly bronchopulmonary dysplasia (BPD), which leads to long-term respiratory morbidity and reduced quality of life, with existing treatments being inadequate for improving both short-term and long-term outcomes.

Method used

Administering insulin-like growth factor-1 (IGF-1) or its agonist, optionally combined with insulin-like growth factor binding protein-3 (IGFBP-3), to premature infants to improve lung development and reduce the incidence of CLD.

Benefits of technology

The administration of IGF-1 and IGFBP-3 significantly reduces the incidence of chronic respiratory morbidity, bronchopulmonary dysplasia, and other complications in premature infants, improving their functional status and long-term developmental outcomes.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

To provide methods for treating Chronic Lung Disease (CLD).SOLUTION: A method comprises administering insulin-like growth factor-1 (IGF-1) or an agonist or analog thereof.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art